Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Procter & Gamble Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Procter & Gamble Co trades at $144.67 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 11.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Procter & Gamble Co pays a 2.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PG | |
|---|---|---|
Market Cap | $29.03B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $167.18 |
52-Week Low | $205.48 | $138.10 |
Enterprise Value | $26.99B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.
Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 18.44% and consistent earnings beats. The company maintains robust cash flow from operations of $17.82B in 2025 and a dividend track record, with a recent partnership with the WNBA signaling strategic brand expansion. Valuation ratios like P/E of 22.12 and P/S of 4.08 reflect a premium to peers amid modest revenue growth.
PG offers stability with high profitability and dividend reliability, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical indicators suggest caution. Key risks include economic sensitivity and competitive pressures, while institutional holdings show mixed sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
